2016 Updated MASCC/ESMO consensus recommendations: Management of nausea and vomiting in advanced cancer

Keyphrases

• Vomiting 100%
• Nausea 100%
• MASCC 100%
• Advanced Cancer 100%
• Consensus Recommendations 100%
• Recommendation Management 100%
• Antiemetics 60%
• Haloperidol 40%
• Octreotide 40%
• Clinical Evidence 20%
• Drug Choice 20%
• Metoclopramide 20%
• Antiemetic Drugs 20%
• Poor Quality 20%
• Panel Member 20%
• Evidence-based Recommendations 20%
• New Guidelines 20%
• Uncontrolled Trial 20%
• Olanzapine 20%
• Committee Membership 20%
• Levomepromazine 20%
• Drug Effectiveness 20%
• Antisecretory Agent 20%
• Bowel Obstruction 20%
• Opioid-induced 20%
• Lack of Evidence 20%
• Guideline-based 20%

Medicine and Dentistry

• Advanced Cancer 100%
• Nausea and Vomiting 100%
• Antiemetic 80%
• Systematic Review 40%
• Octreotide 40%
• Haloperidol 40%
• Drug Efficacy 20%
• Metoclopramide 20%
• Parasympatholytic 20%
• Bowel Obstruction 20%
• Levomepromazine 20%
• Stomach Secretion Inhibitor 20%
• Base 20%
• Clinician 20%
• Olanzapine 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Nausea and Vomiting 100%
• Advanced Cancer 100%
• Antiemetic Agent 80%
• 4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol 40%
• Octreotide 40%
• Olanzapine 20%
• Cholinergic Receptor Blocking Agent 20%
• Intestine Obstruction 20%
• Levomepromazine 20%
• Stomach Secretion Inhibitor 20%
• Base 20%
• Metoclopramide 20%